Humanigen seeks FDA approval for COVID-19 drug

By The Science Advisory Board staff writers

May 28, 2021 -- Humanigen requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to use its drug lenzilumab in hospitalized COVID-19 patients.

This application follows positive results from the LIVE-AIR phase III clinical trial that showed lenzilumab improved the likelihood of survival without ventilation in newly hospitalized COVID-19 patients.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.